Tharimmune, Inc. (NASDAQ:THAR) Sees Significant Drop in Short Interest

Tharimmune, Inc. (NASDAQ:THAR) saw a large decline in short interest during the month of March. As of March 15th, there was short interest totalling 22,800 shares, a decline of 69.9% from the February 29th total of 75,700 shares. Based on an average daily trading volume, of 675,100 shares, the short-interest ratio is presently 0.0 days. Approximately 0.2% of the shares of the stock are short sold.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Tharimmune stock. Virtu Financial LLC bought a new position in shares of Tharimmune, Inc. (NASDAQ:THAR) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 105,033 shares of the company’s stock, valued at approximately $53,000. Virtu Financial LLC owned about 0.89% of Tharimmune at the end of the most recent reporting period. Institutional investors and hedge funds own 1.16% of the company’s stock.

Tharimmune Stock Up 0.5 %

Shares of Tharimmune stock traded up $0.00 on Thursday, hitting $0.44. 15,968 shares of the company were exchanged, compared to its average volume of 557,724. The stock has a market cap of $5.11 million, a PE ratio of -0.03 and a beta of 1.57. The stock’s 50-day moving average is $0.40. Tharimmune has a 1-year low of $0.34 and a 1-year high of $33.25.

Tharimmune Company Profile

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).